🦠 Stewardship Impact on Resistance Trend Simulator

The Pre-Stewardship Baseline — Why Resistance Trends Upward Unchecked

Before a structured stewardship program exists, antibiotic use in most hospitals is driven by defensive prescribing, broad empiric coverage that is rarely de-escalated, and prolonged treatment courses that exceed guideline-recommended durations. Each of these practices independently accelerates selection pressure for resistant organisms, and their combined effect compounds year over year.

• 32%: MRSA baseline prevalence (of S. aureus isolates, US acute-care median)
• 9%: CRE baseline prevalence (of Enterobacterales, high-burden facility)
• 8.5: C. diff incidence (per 10,000 patient-days)
• <20%: De-escalation rate (no program) (of empiric regimens narrowed by day 3)

How unmanaged prescribing drives the baseline curve upward

In the absence of a formal stewardship structure, several well-documented prescribing patterns accelerate resistance selection simultaneously:

Broad-spectrum empiric therapy without de-escalation: • Clinicians default to carbapenems, anti-pseudomonal beta-lactams, or vancomycin for undifferentiated sepsis • Once cultures return, therapy is frequently continued unchanged rather than narrowed — audits typically find de-escalation occurs in fewer than 1 in 5 eligible cases without active prompting • Each additional day of unnecessary broad-spectrum exposure measurably increases the odds of colonization with a resistant organism

Excess duration of therapy: • Many common infections (community-acquired pneumonia, uncomplicated cystitis, intra-abdominal infection with source control) have guideline-supported short courses (5–7 days), yet historical practice defaults to 10–14 days • Each extra antibiotic-day is an independent risk factor for both individual-patient colonization and population-level selection pressure

Diagnostic uncertainty and defensive prescribing: • Without rapid diagnostics or structured review, clinicians treat "possible infection" empirically and continue therapy pending clinical improvement rather than a specific stop criterion • This drives cumulative days of therapy (DOT) per 1,000 patient-days well above benchmarked peer institutions

The compounding effect on the resistance curve: • Selection pressure is dose- and duration-dependent: resistant subpopulations that survive early therapy proliferate under continued antibiotic exposure • Cross-transmission in the hospital environment (contaminated surfaces, hand hygiene lapses, inadequate contact precautions) then disseminates resistant clones between patients, amplifying the population-level prevalence increase • Without intervention, published surveillance data (CDC National Healthcare Safety Network, WHO GLASS) show MDRO prevalence climbing 1–3 percentage points annually in high-use facilities

CDC surveillance data consistently show that facilities in the top quartile of antibiotic use (measured in days of therapy per 1,000 patient-days) have MRSA and CRE prevalence 1.5–2× higher than facilities in the bottom quartile — even after adjusting for patient case-mix, establishing antibiotic exposure as an independently modifiable driver of the baseline trend.

Launching the Bundle — CDC's Seven Core Elements of Hospital Antibiotic Stewardship

The CDC's Core Elements of Hospital Antibiotic Stewardship Programs (updated 2019) define the evidence-based structural bundle that every accredited US hospital stewardship program is now expected to implement. Rather than a single intervention, it is a coordinated set of organizational, clinical, and educational components that together create sustained downward pressure on inappropriate antibiotic use.

• 7: CDC core elements (leadership → reporting)
• >95%: US hospitals with a program (Joint Commission requirement since 2017)
• 20–30%: DOT reduction, typical bundle (days of therapy per 1,000 patient-days)
• ~6 mo: Time to formal accreditation (baseline audit to steady-state operation)

The seven core elements and what each contributes

1. Hospital leadership commitment: • Dedicated financial and human resources (protected pharmacist/physician FTE time) • Institutional statements of support signed by C-suite and medical staff leadership

2. Accountability: • A single physician (and typically a co-leading pharmacist) formally accountable for program outcomes • Reports directly to infection prevention and quality committees

3. Pharmacy expertise (drug expertise): • Board-certified infectious diseases pharmacist(s) co-leading day-to-day operations • Pharmacy-driven dose optimization, renal adjustment, and IV-to-oral conversion protocols

4. Action — the two flagship interventions: • Prospective audit and feedback (PAF): a stewardship pharmacist/physician reviews active antibiotic orders (typically at 48–72h) and makes real-time, non-punitive recommendations to the prescribing team • Formulary restriction and pre-authorization: select broad-spectrum agents (carbapenems, anti-MRSA agents, newer beta-lactam/beta-lactamase-inhibitor combinations) require stewardship approval before dispensing beyond an initial empiric dose

5. Tracking: • Standardized metrics — days of therapy (DOT) per 1,000 patient-days, antibiotic-specific use rates, C. difficile incidence, MDRO prevalence — reported to NHSN Antimicrobial Use and Resistance (AUR) Module

6. Reporting: • Regular, unit-level feedback to prescribers and department chairs; benchmarking against peer institutions

7. Education: • Structured onboarding for new clinicians, ongoing case-based teaching, and guideline dissemination (institution-specific empiric therapy guidelines aligned with local antibiogram)

A 2017 Cochrane systematic review (Davey et al., 340+ studies) found that stewardship interventions combining restriction with PAF increased compliance with appropriate prescribing by roughly 15 percentage points and shortened duration of therapy without increasing mortality or hospital length of stay — the evidentiary foundation for CDC's recommendation to pair both interventions rather than deploy either alone.

The Early Plateau — Why Year One Looks Disappointingly Flat

A near-universal finding across published stewardship implementation studies is that the first 6–12 months show minimal measurable change in resistance prevalence, even while process metrics (days of therapy, guideline concordance) are already improving substantially. This lag is expected, biologically grounded, and should be explicitly anticipated in program planning and stakeholder communication.

• <2pp: Typical year-1 prevalence change (percentage points, target organisms)
• 10–15%: DOT reduction already visible (process metric moves first)
• 6–18 mo: Colonized-patient reservoir half-life (persists after prescribing changes)
• 12–24 mo: Typical time to significance (before prevalence decline is statistically robust)

The mechanisms behind the lag between prescribing change and resistance decline

Process metrics move immediately; outcome metrics move slowly. This is the single most important expectation-setting concept in stewardship program evaluation:

Existing colonization reservoir: • Patients already colonized with MRSA, CRE, or carrying ESBL-producing organisms in their gut flora remain colonized for months regardless of current prescribing practice • Colonization pressure (the proportion of patients on a unit already colonized) continues driving new transmission events until the reservoir itself shrinks through natural clearance, discharge, and reduced re-acquisition

Prescribing culture change is gradual: • PAF recommendations are initially accepted at 60–70% rates; acceptance climbs to 85–90%+ only after 6–12 months as trust and workflow integration mature • Some services and individual prescribers show slower adoption curves, requiring targeted academic detailing

Surveillance and reporting lag: • Resistance surveillance data (antibiograms, NHSN AUR reports) are typically compiled and reported quarterly to annually, meaning the earliest true signal is often not visible to the program team until 9–12 months in • Statistical power to detect a true decline against normal month-to-month variation requires accumulating enough patient-days — segmented regression / interrupted time-series analysis (the standard stewardship evaluation method) generally needs 12+ pre- and post-intervention data points

Why this matters for program sustainability: • Administrative support can erode if leadership expects immediate resistance-rate improvement • Programs that survive the lag phase by tracking and reporting process metrics (DOT reduction, PAF acceptance rate, restricted-agent approval rate) alongside outcome metrics retain institutional buy-in through the plateau

Interrupted time-series analyses of stewardship programs consistently show a visible inflection point in resistance trends beginning around month 12–18, not month 1 — programs that abandon efforts before this point based on early "no effect" readings are discarding an intervention that has not yet had time to manifest its full benefit.

Years 2–4 — The Curve Bends: Quantifying the Decline

Between years two and four, the cumulative reduction in selective antibiotic pressure combined with a shrinking colonized-patient reservoir produces the steepest, most statistically robust portion of the resistance decline. This is the phase captured by most published before-after and interrupted time-series stewardship evaluations.

• 32%: CDI incidence reduction (meta-analysis) (Baur et al. 2017, Lancet Infect Dis)
• ~26%: MDRO acquisition/infection reduction (same pooled meta-analysis, 32 studies)
• 19.1%: Antibiotic consumption reduction (pooled DOT reduction, restriction+PAF)
• ~1.3pp/yr: Annualized CRE decline, years 2–4 (model trajectory, this simulation)

The evidence base for the magnitude of decline

Baur et al. (Lancet Infectious Diseases, 2017) performed the largest published meta-analysis of stewardship program impact on resistance and C. difficile outcomes, pooling 32 studies:

• Stewardship interventions were associated with a 32% relative reduction in incidence of infections caused by antibiotic-resistant bacteria (95% CI 20–42%) • A 26% relative reduction in incidence of infections caused by any multidrug-resistant organism • Most pronounced effect: a 32% relative reduction in Clostridioides difficile infection incidence — driven primarily by reduced use of high-risk agents (fluoroquinolones, clindamycin, third-generation cephalosporins) • Effect sizes were larger in studies combining restrictive interventions (formulary restriction/pre-authorization) with persuasive interventions (PAF, guidelines, education) than either approach alone

Davey et al. Cochrane review (2017, updated from 2013): • Pooled 221 studies: stewardship interventions reduced antibiotic consumption by 19.1% (interrupted time-series data) without evidence of increased mortality • Duration-shortening interventions (aligning treatment length to guideline-recommended durations) were independently associated with reduced adverse events and cost

Why years 2–4 show the steepest decline in this simulation: • Cumulative antibiotic-pressure reduction compounds: each additional year of lower prescribing further shrinks the colonized reservoir feeding new transmission • PAF acceptance rates plateau near their ceiling (85–90%) by year 2, meaning nearly all eligible interventions are now being executed • Concurrent infection-prevention gains (hand hygiene compliance, contact precaution adherence, environmental cleaning) — often strengthened alongside stewardship rollout — compound the antibiotic-driven signal

A single-center CRE program described by the CDC (Vital Signs report) achieved a >50% relative reduction in CRE clinical incidence within 3 years of combining stewardship restriction, active surveillance cultures, and contact precautions — illustrating that the steepest gains typically arrive when antibiotic stewardship is paired with, not substituted for, core infection prevention practice.

Years 5 and Beyond — Sustained Low-Resistance Equilibrium

By year five, resistance prevalence for the targeted organisms stabilizes at a new, durably lower baseline. The program has transitioned from an active change initiative to embedded standard-of-care infrastructure — ongoing surveillance and periodic reinforcement, rather than intensive new intervention, are what maintain the gain against reintroduction of resistant strains and prescribing drift.

• 16%: MRSA prevalence at equilibrium (vs. 32% baseline — 50% relative reduction)
• 2.5%: CRE prevalence at equilibrium (vs. 9% baseline — 72% relative reduction)
• 2.3/10k: C. diff at equilibrium (vs. 8.5/10k baseline — 73% relative reduction)
• ~85%: Programs sustaining gains at 5yr (when core elements remain funded)

What "standard of care" maintenance looks like

Reaching equilibrium does not mean the program can be dismantled — resistance prevalence rebounds if selective pressure is reintroduced. Mature programs shift emphasis toward maintenance activities:

Continuous surveillance, lighter-touch review: • PAF frequency can often shift from reviewing all broad-spectrum starts to targeted high-risk classes (carbapenems, anti-MRSA agents) plus outlier prescribers identified by dashboard analytics • Antibiogram-driven empiric guideline updates continue annually, adjusting recommendations as local susceptibility patterns evolve

Workforce turnover management: • New physicians and pharmacists rotate in continuously; sustained education modules and onboarding checklists prevent erosion of institutional prescribing culture • Structured case conferences keep stewardship principles visible even after the "launch energy" of the initial rollout fades

Guarding against complacency and resistance re-emergence: • Periodic audits confirm PAF acceptance rates and restricted-agent approval turnaround remain within target • Any uptick in target-organism incidence triggers rapid root-cause review (new admission source, ICU outbreak, prescribing drift) before it compounds

Expanding scope once core elements are stable: • Many mature programs add outpatient/ambulatory stewardship, transitions-of-care antibiotic review, and diagnostic stewardship (see companion simulation on rapid diagnostics) as the next increment of impact • Antifungal stewardship and biosimilar/novel agent stewardship are common next frontiers once the antibacterial program has reached steady state

The equilibrium reached is a new set point, not a ceiling — programs that continue investing in diagnostic-driven de-escalation and expand stewardship into transitions of care typically see a second, smaller step-decline in resistance prevalence in years 6–10, as remaining sources of inappropriate use are addressed.

What Would Have Happened — The Counterfactual Trajectory

The most persuasive way to communicate stewardship impact to hospital leadership is the counterfactual comparison: reconstructing, using published effect-size estimates, what the resistance trajectory would plausibly have looked like had the program never launched. The widening gap between the two curves represents infections, resistant colonizations, and C. difficile cases averted — and the downstream costs avoided with them.

• 26pp: MRSA gap at year 8 (16% actual vs. 42% counterfactual)
• 16pp: CRE gap at year 8 (2.5% actual vs. 18.5% counterfactual)
• 12.9/10k: C. diff gap at year 8 (2.3 actual vs. 15.2 counterfactual)
• ~180/yr: Estimated CDI cases averted, 500-bed hosp. (at year-8 equilibrium, illustrative)

Constructing and interpreting the counterfactual curve

Because no hospital can simultaneously run a program and not run it on the same population, the counterfactual trajectory is necessarily modeled rather than directly observed. Rigorous approaches include:

Interrupted time-series (ITS) segmented regression: • The gold-standard quasi-experimental method for stewardship evaluation • Fits a regression line to the pre-intervention trend, then projects that trend forward as the counterfactual, comparing it against the observed post-intervention trend • Captures both a level change (immediate step) and a slope change (change in trajectory) attributable to the intervention

Matched control-unit or control-hospital designs: • Comparable units/hospitals that did not implement (or delayed implementing) the intervention serve as an empirical counterfactual • Difference-in-differences analysis isolates the program-attributable effect from secular trends affecting all facilities (e.g., regional antibiotic use patterns, background resistance importation)

Published effect-size extrapolation (the method illustrated in this simulator): • Applies pooled relative-risk reductions from meta-analyses (Baur et al. 2017: 32% CDI reduction, 26% MDRO reduction; Davey et al. 2017: 19.1% consumption reduction) to a facility's own pre-intervention trajectory • Useful for institutional business cases and leadership communication, though less rigorous than a facility-specific ITS analysis

Why the gap widens over time rather than staying constant: • The counterfactual trend continues compounding upward (unchecked selection pressure, continued cross-transmission) while the actual trend flattens and then declines • This divergence is the epidemiological signature of an effective, sustained intervention — a program that only prevents further increase (flat vs. rising) still generates a growing gap over a multi-year horizon, even without an absolute decline

Modeling a 500-bed hospital over 8 years using the Baur et al. pooled effect sizes suggests roughly 1,400 resistant-organism infections and several hundred C. difficile cases are averted cumulatively compared to the no-stewardship counterfactual — translating into millions of dollars in avoided excess length-of-stay and treatment costs, the core argument used in nearly every hospital stewardship program business case.